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Relevance of Experimental Studies to
Human Risk
by F. K. Dietz,*t J. C. Ramsey* and P. G. Watanabe*
Confidence in the extrapolation ofanimal toxicity data to humans can be enhanced by
the application of pharmacokinetic concepts integrated with chronic toxicity data and
knowledge of a chemical's mechanism(s) of toxicity. Basic pharmacokinetic concepts
(including dose-dependent or Michaelis-Menten kinetics) and their relationship to the
risk estimation process are discussed using vinyl chloride and styrene as specific exam-
ples. Species differences in metabolic rates must be considered in order to arrive at
realistic estimates ofhuman risk to vinyl chloride-induced liver angiosarcomas utilizing
vinyl chloride toxicity data observed in rats. Because small animal species generally
metabolize chemicals morerapidlythanlarger species on abody surface areabasis, small
animals should be more sensitive to chemicals (such as vinyl chloride) that exert their
toxicities via the metabolic formation of toxic products. Inhaled styrene is a chemical
whose clearance from the blood at low exposure levels in both rats and humans follows
first-order kinetics. However, at higher exposure levels, the pharmacokinetic fate of
styrene in rats is dose-dependent, suggesting a saturation of styrene metabolism. These
data indicate that any extrapolation ofobservable toxicity at elevated exposure levels in
rats to anticipated responses at lower levels in either rats or humans may be invalid. An
integration of the foregoing concepts provides a sound scientific basis for the use of
experimental animal data to predict the risk to humans from chemical exposure.
Introduction
Chemically induced carcinogenicity is one type
oftoxic response that has received primary atten-
tion in recent years. The potential lethality of
cancer, combined with its generally irreversible
nature and long latent period are all characteris-
tics that have placed carcinogenesis in the fore-
front ofpublic concern. Many chemicals shown to
be mutagenic in short-term in vitro studies and/or
carcinogenic in long-term animal studies have
consequently been considered as potential human
carcinogens. This conclusion is typically based on
studies ofanimal models performed under tightly
controlled experimental conditions in which po-
tentially interfering variables are kept to a mini-
mum. Although a basic toxicological goal is to
evaluate the risk to man associated with exposure
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to potentially harmful substances, interspecies
variation in response may often preclude a simple
extrapolation of animal toxicity to that antici-
pated in man. The purpose ofthis presentation is
to review and emphasize the importance of ani-
mal pharmacokinetic studies in properly imple-
menting animal toxicity data to predict human
risk from chemical exposure.
Pharmacokinetic Concepts and
Dynamics of Toxicity
Pharmacokinetics is a study ofthe dynamics of
absorption, distribution, metabolism and excre-
tion of a chemical within the body. Pharmaco-
kinetic studies of a chemical as a function of
administered dose often provide valuable infor-
mation on how a chemical's overall biological fate
may change in response to different amounts
within the body. Since many toxic responses to
chemical exposure are not only dependent on the
amount of a chemical that reaches a target site
but also on how long a sensitive site might be
exposed, a comparison of the pharmacokinetic
fate of a chemical between different species ofDIETZ, RAMSEY AND WATANABE
animals can provide data about differential sus-
ceptibility relating to interspecies extrapolation
oftoxicity data.
A classical approach to pharmacokinetic analy-
sis depicts the body as consisting of a system of
compartments. An individual compartment gen-
erally refers to all tissues, organs, cells and/or
fluidswithinthe bodyforwhichthe rate ofuptake
and loss ofa chemical is sufficiently similar as to
preclude further kinetic resolution. Gehring et al.
(1) have provided a detailed description of phar-
macokinetic compartments and their use in eval-
uating toxicity data, and consequently no de-
tailed discussion will be included here. While
compartments do not always have direct physio-
logical or anatomical counterparts when ana-
lyzed kinetically, they constitute a basic tool by
which quantitative expressions describing the
fate ofa chemical within the body can be derived.
Dose-Independent Pharmacokinetics
Over a range of selected dose levels, many
chemicals exhibit first-order kinetics which can
be referred to as being "linear." For these chemi-
cals, the rates ofabsorption, distribution, metabo-
lism and elimination from the body are propor-
tional to the concentration or amount of the
chemical within the body. As a consequence of
this proportionality, the rate constants of all
these processes are thus independent of the ad-
ministered dose. In a simplified fashion, first-
order kinetics may be expressed by the equation:
rate = -dCldt = kC
in which C is the concentration ofthe chemical in
the body at time t and k is the rate constant for
the given process. As long as first-order kinetics
apply andthus the rate constants for all processes
responsible for a chemical's pharmacokinetic fate
are independent ofadministered dose, tissue con-
centration and consequent toxicity should also be
proportional to administered dose.
Dose-Dependent Pharmacokinetics
In actuality, many reactions that influence a
chemical's pharmacokinetic fate are not indepen-
dent of administered dose, but are instead dose-
dependent. In this situation, saturable active
transport systems or metabolic reactions that of-
ten play key roles in the prevention or enhance-
ment ofchemical toxicity are not adequately de-
scribed by first-order kinetics. As a consequence,
the administration of high dose levels, as fre-
quently done in long-term animal bioassays, may
overwhelm these processes and result in a dispro-
portionate increase in blood and/or tissue concen-
tration and possibly elicit a toxic response.
The rates of saturable processes are often de-
scribed by Michaelis-Menten or dose-dependent
kinetics according to the equation:
rate = -dCldt = VmaxC/Km +C
In this equation, -dCldt is the rate ofchange in
the concentration ofthe chemical's concentration
at time t, Vmax is the maximum velocity of the
process and Km is the Michaelis constant or that
concentration at which the rate of the process is
at a value ofone-halfVmax. There are two limiting
situations to this equation. When the concentra-
tion (C) is much greater than Km, the Michaelis-
Menten equation approaches a limit of:
rate = -dCldt Vmax C>>Km
In this situation, the rate ofthe process is limited
by the value Vmax, and, as C increases, the rate of
the reaction remains constant. It is in this concen-
tration range (C>>Km) that the biological proc-
esses governed by this type of kinetic behavior
have become overwhelmed and can be considered
to be saturated.
Conversely, ifthe concentration C is much less
thanKm, the rate ofthe processes describedby the
Michaelis-Menten equation can be approximated
by:
rate = -dCldt kC C<<Km
where k = VmaxKm. Under these conditions, the
rate of the process remains proportional to the
chemical's concentration and all ofthe previously
described concepts for first-order kinetics regard-
ing proportionality between blood and tissue con-
centration and toxicity apply.
Use of Animal Studies for
Predicting Human Toxicity
Recent authors have suggested that there are
at least five potential factors responsible for spe-
cies variations in response to chemical exposure
(2). Collectively, these factors include absorption,
distribution, metabolism, site and mechanism of
action and excretion of the chemical from the
body. It is of interest to note that an analysis of
the dynamics of many, if not all, of these factors
as a function of administered dose level consti-
tutes what has been previously described as a
pharmacokinetic study.
In utilizing animal studies to predict possible
human toxicity, it is important to determine if
the toxicity resulting from chemical exposure is
due to the parent chemical itself or rather to an
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active metabolite generated via metabolic proc-
esses occurring within the animal. It is commonly
accepted that metabolism can either lead to de-
toxification or activation, depending on the toxi-
cological potential ofthe parent compound and/or
its possible metabolites. Consideration ofthis in-
formation is important for the extrapolation of
results from animal toxicity studies to man, since
there may be relative species differences in the
activity ofenzymes responsible for chemical me-
tabolism. As pointed out by Rall (3), it is often
possible to estimate the relative sensitivity of
different species to a chemical by using an ap-
proximation that the basal metabolic rate is
roughly proportional to the body surface area.
This suggests that if factors other than metabo-
lism are ignored, a large animal species is more
sensitive to a directly toxic agent than a small
animal species (Table 1). In contrast, a large ani-
mal species should then be less sensitive to toxic-
ity mediated by a metabolic activation than a
smaller species (4). It should be emphasized, how-
ever, that for some types of metabolic activation
the relative rates may not only be a simple func-
tion of body size. For example, the metabolic
activation of 2-acetaminofluorene involves the
formation ofan active sulfate, andthe species and
organ sensitivity of the tumorigenicity of this
agent correlates well with the level ofsulfotrans-
ferase enzyme activity (5). Since the rat has a
higher level ofsulfotransferase thanthe mouse, it
develops more tumors when exposedto an equiva-
lent amount of 2-acetaminofluorene. In this in-
stance, the larger animal species is more sensi-
tive to the effects of the metabolically activated
agentthan the smaller species. Thus, the reliabil-
ity of interspecies extrapolation depends to a
large degree upon how much is known of the
details ofmetabolism and how metabolism affects
toxicity in the species ofinterest.
Pharmacokinetic Concepts and
Risk Estimation
Many mathematical models are commonly used
in extrapolating an observed carcinogenic re-
sponse in animal bioassays atrelatively high dose
levels (6). While these models differ from each
other by the rapidity in which a zero response is
approached as the dose level approaches zero,
they are similar in that they usually assume that
a zero response occurs only when the dose level
equals zero. Another feature common to these
models istheir assumption thatthe concentration
ofthe carcinogenic entity is directly proportional
to the dose level of the administered chemical.
Table 1. Predicted relative cancer risk from equivalent
doses (mg/kg) calculated on the basis of(body
weight).a
Predicted relative cancer risk
Directly toxic Metabolically activated
Species agents agents
Man (70 kg) 1.00 1.00
Dog (20 kg) 0.66 1.52
Rabbit (3 kg) 0.35 2.85
Rat (0.5 kg) 0.18 5.58
Mouse (0.03 kg) 0.08 13.20
aAfter Rall (3).
This assumption applies whether the carcino-
genic entity is produced via a metabolic activa-
tion ofthe parent chemical or whether the parent
chemical itselfis the primary toxicant. An impor-
tant consequence ofthis assumption is that toxic-
ity or carcinogenicity is also expected to be pro-
portional to administered dose level. Recent
studies ofseveral chemicals, including vinyl chlo-
ride and styrene, illustrate how an understanding
of the pharmacokinetic fate of these compounds
as influenced by the magnitude of administered
dose can be used to evaluate animal toxicity data
in order to predict the hazard to man from expo-
sure to these agents.
Vinyl Chloride
An example of dose-dependent pharmaco-
kinetics that directly relates to carcinogenic risk
estimation in man is that of inhaled vinyl chlo-
ride (7, 8). Vinyl chloride has been demonstrated
to induce hepatic angiosarcomas in rats at expo-
sure levels ranging from 10 to 10,000 ppm, with
an essentially flat dose-response curve at expo-
sure levels from 1,000 to 10,000 ppm (9). Numer-
ous studies have indicated that a reactive metab-
olite of vinyl chloride is likely to be the
carcinogenic entity for this halogenated ethylene
rather than the parent compound itself (10-15).
Other studies have shown that the bioactivation
ofvinyl chloride in rats is a saturable process that
follows Michaelis-Menten kinetics becoming
overwhelmed at high exposure levels, thereby
limiting the in vivo production ofthe toxic metab-
olite (7, 16-19). As a consequence ofthis satura-
ble metabolic activation, Gehring et al. (7) have
shown that the toxicity or carcinogenicity in rats
resulting from vinyl chloride exposure is not di-
rectly proportional to all exposure concentra-
tions. Alternatively, these authors found it was
possible to relate the observed carcinogenicity in
rats to the amount ofvinyl chloride metabolized
after pharmacokinetic parameters describing the
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saturable bioactivation ofvinyl chloride were de-
termined.
In accordance with these observations of the
kinetic behavior ofvinyl chloride in rats, Gehring
et al. (7, 8) utilized similar pharmacokinetic con-
cepts to estimate the amount of vinyl chloride
metabolized in man. Their prediction incorporat-
ed the concepts that vinyl chloride bioactivation
in man was a saturable process as observed in
laboratory animals and that the metabolic proc-
ess responsible for vinyl chloride metabolism in
mammals was related to differences in body sur-
face area. Using this methodology, these authors
predicted that man's rate ofvinyl chloride bioac-
tivation wouldbe much less than that observed in
rats, resultinginadecreased sensitivity ofmanto
the tumorigenic effects of vinyl chloride (7, 8).
Recent data from other laboratories on the rate of
vinyl chloride metabolism have provided addi-
tional support for this conclusion. In studies of
the pharmacokinetics of vinyl chloride in differ-
ent species (including man), Buchter et al. (20,
21) andFilser and Bolt (22) have confirmedthat a
marked species variation in vinyl chloride metab-
olism does indeed exist (Table 2). These investiga-
tors found that mice and rats metabolized vinyl
chloride at a rate approximately 5-12 times that
for man. In contrast to the results observed in
these rodent species, rhesus monkeys were found
to metabolize vinyl chloride at a rate that closely
paralleled that seen in man. Collectively, these
results are significant in that they confirm the
predictions reached by Gehring et al. (7, 8), who
used pharmacokinetic concepts to predict differ-
ences in the relative rates of vinyl chloride me-
tabolism in rats versus man.
Styrene
Styrene is anotherexample ofachemical whose
metabolic elimination in experimental animals is
dose-dependent. In an analysis ofthe pharmaco-
kinetic fate of styrene in rats following a 6-hr
inhalation exposure to 80, 200, 600 or 1200 ppm,
Ramsey andYoung (23) observed thatthere was a
marked dose dependency in the elimination of
styrene from the blood. Figure 1 depicts a plot of
the blood styrene concentration versus time data
in animals exposed to 80 or 1200 ppm for 6 hr.
Other animals were left inthe exposure chambers
for periods of up to 24 hr in order to establish
whether plateau blood levels were achieved. Note
that a disproportionality exists between maxi-
mum blood concentration and exposure level. At
an exposure level of 80 ppm, the maximum
styrene concentration was 0.8 ,ug/mL, while at
1200 ppm the maximum blood concentration
reached a value of 64 pig/mL. Thus, as exposure
concentration increased by 15-fold, the maximum
blood concentration increased over 80-fold, indi-
cating a dose dependency in the pharmacokinetic
profile of styrene. As reviewed by the original
authors (23), these and other data indicated that
thecapability oflaboratory animalsto metabolize
styrene becomes overwhelmed at exposure con-
centrations somewhere between 200 and 600
ppm. These results indicate that any extrapola-
tion ofanimal toxicity data observed at exposure
levels of 600 ppm and above to anticipated re-
sponses in animals atlower levelsmaybe invalid.
How do these results relatetothe extrapolation
of styrene toxicity data in laboratory animals to
that in man? Such an extrapolation can be
greatly facilitated by a direct pharmacokinetic
comparison of the chemical in question between
both species. Accordingly, Ramsey and Young
Table 2. First-order metabolic clearance rates for vinyl
chloride in man versus other species.a
Species
Man
Monkey
Rat
Mouse
Clearances,
L/hr/kg body weight
2.02
3.55
11.00
25.60
aData from Buchter et al. (20,21) and Filser and Bolt (22).
Ag Styrene/
ml Blood
Hours
FIGURE 1. Blood styrene concentration inratsexposedto 80 or
1,200 ppm. Data from Ramsey and Young (23).
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FIGURE 2. Blood styrene concentration in humans exposed to
80 ppm for 6 hr. Data from Ramsey and Young (23).
(23) conducted a pharmacokinetic study of in-
haled styrene in human volunteers exposed to 80
ppm for 6 hr. Figure 2 depicts the blood styrene
concentration during and after exposure in the
four volunteers. Note that the blood styrene con-
centration rose to a maximum of 0.9 pig/mL at 6
hr and declined in a linear fashion. A comparison
ofthese results with those ofFigure 1 indicates a
marked similarity between the pharmacokinetic
fate ofstyrene in man andrats following exposure
to 80 ppm. These authors concluded thatthis type
ofsimilarity lends confidence to the extrapolation
oftoxicity data observed in laboratory animals at
levelsbelow 80ppmto thatanticipated in man. In
contrast, the demonstration of a saturable elimi-
nation of styrene from laboratory animals at
higher exposure levels precludes the use oftoxic-
ity data obtained at high levels to predict possible
risks to humans at lower exposure levels.
Conclusions
In summary, it should be noted that animal
studies of pharmacokinetic behavior only repre-
sent one segment ofthe total data base ofinterre-
lated information required to make a rational
extrapolation oftoxicity data observed in labora-
tory animals to anticipated responses in man.
Other authors have demonstrated that the risk
estimation process is greatly enhanced when ani-
mal studies ofpharmacokinetic behavior are inte-
grated with observations ofchronic toxicity and a
knowledge ofmechanisms oftoxicity such as the
production of active metabolites that interact
with critical macromolecular sites. Collectively,
an evaluation ofthe relationships between these
parameters and toxicity in experimental animals
will improve the estimation ofrelative degrees of
risk to man associated with chemical exposure.
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